PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

"Cuddle hormone" oxytocin may provide pain relief and help curb harmful opioid use

2024-09-10
(Press-News.org) In the midst of America’s growing opioid crisis, a much healthier alternative to long-term pain management is emerging — one affectionately known as “the cuddle hormone,” or oxytocin.

University of Florida researchers are currently investigating whether a synthetic version of this naturally-occurring human hormone can be used in conjunction with prescription drugs to help curb opioid addictions, especially in susceptible older adults. An interdisciplinary research team is conducting the two-year study, with $414,375 in funding from the National Institutes of Health, and completion is expected in April 2025.

“The idea is that physicians could potentially prescribe, in combination, an opioid and oxytocin as an acute pain management option, while at the same time lessening the likelihood of developing an addiction to opioids,” said Meredith Berry, Ph.D., an assistant professor in the UF College of Health & Human Performance’s Department of Health Education & Behavior.

Berry is one of the study’s lead researchers, along with Yenisel Cruz-Almeida, Ph.D., an associate professor in the UF College of Dentistry’s Department of Community Dentistry and Behavioral Science and the associate director of the Pain Research & Intervention Center of Excellence; and Natalie Ebner, Ph.D., a professor in the UF College of Liberal Arts and Sciences’ Department of Psychology and associate director of the Center for Cognitive Aging and Memory Clinical Translational Research at the McKnight Brain Institute.

The team is analyzing whether oxytocin — which produces positive feelings in the body and is the hormone most known for its role in stimulating child labor, supporting parent-child bonding, and other social-affiliative processes — can be used as a potential pain reducer while simultaneously decreasing the desire for long-term opioid use. While opioids can be highly effective for short-term pain relief, Berry said, pharmaceutical alternatives for acute pain could lead to less addicting habits. 

In a double-blind, randomized, placebo-controlled study, 30 participants between the ages of 55 and 85 with a history of some opioid use will take synthetic oxytocin via a nasal spray, or take a placebo shortly after administering oral oxycodone.

Subjects will then rate how much they like the drugs, and their cardiovascular, respiratory, cognitive, and affective responses to the drugs will be tracked. Additionally, pain measures will be collected by inducing acute mechanical pain, including subtle force applied to participants’ thighs, and thermal pain, such as cold and heat applied to participants’ hands.

Ebner will analyze the changes in mood and the cognitive outcomes, Cruz-Almeida will examine the effects of the drugs versus placebo on pain response, and Berry will evaluate the potential of reduced opioid addiction to understand the effects of the drug combinations. Physicians from the UF College of Medicine are also involved in the study to oversee participant safety.

“Collaborating with a multidisciplinary team — each member bringing expertise from various fields yet united by a deep understanding of pain and addiction — allows us to evaluate the data and implications through a diverse and comprehensive lens,” Berry said.

Developing innovative, non-addictive options for pain management continues to be critical work in the current health landscape. In 2021, approximately 60 million people used opioids, and 39.5 million people developed a drug use disorder, according to the World Health Organization.

In 2017, the U.S. Department of Health and Human Services declared the opioid crisis a national public health emergency. And, as recently as June, the department issued a renewal of determination, affirming that the opioid crisis remains a public health emergency.

Midlife and older adults, who are frequently prescribed opioids for pain, are developing opioid addictions at an increased rate. Incorporating synthetic oxytocin into these patients’ pain management routines could be a game changer.

END


ELSE PRESS RELEASES FROM THIS DATE:

Study reveals mechanism that activates glucose production in the liver in response to stress

2024-09-10
A study led by Brazilian researchers has produced a detailed description of the morphology of the nerves in the liver and how they control production of glucose when the organism is under stress. This process is known as hepatic gluconeogenesis. It is a key metabolic function of the liver that helps maintain a normal blood sugar level, especially when fasting and at times of high energy needs.  An article on the study, which entailed experiments with mice, is published in the journal Metabolism. According to the authors, the sympathetic nerves that stimulate the release of noradrenaline in the liver helped ...

Aumolertinib maintenance after chemoradiotherapy in stage III non-small cell lung cancer improves PFS compared to placebo

Aumolertinib maintenance after chemoradiotherapy in stage III non-small cell lung cancer improves PFS compared to placebo
2024-09-10
(San Diego, Calif.--September 9, 2024, 10:05 a.m.) -- The epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-free survival compared to placebo without any significant new adverse reactions, according to data from the POLESTAR study presented today at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer. Consolidation therapy with durvalumab is established as the standard of care for patients who do not experience disease progression following concurrent chemoradiotherapy. However, it is unknown what the specific benefit ...

Weight loss of up to 13% achieved in three months with once-a-day tablet, phase 1 trial finds

2024-09-10
Individuals who received a once-a-day oral weight loss drug lost up to 13% of their body weight over three months, the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September) will hear. Amycretin, which is being developed by the Danish pharmaceutical company Novo Nordisk A/S, mimics the action of two peptide hormones in one single molecule. Amycretin is both an amylin and glucagon-like peptide-1 (GLP-1) receptor agonist. Both of these play a key role in appetite regulation ...

Time-restricted eating improves blood sugar control in adults at risk of type 2 diabetes regardless of time of day

2024-09-10
Restricting the eating window to 8 hours a day significantly improves blood glucose control in adults at risk of type 2 diabetes irrespective of whether it is earlier or later in the day, according to a randomised crossover trial to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept). “Our study found that restricting eating to a window of 8 hours per day significantly improved the daily time spent in the normal blood glucose range and reduced fluctuations in blood glucose levels. However, altering the 8-hour restricted eating period ...

Individuals with complications of diabetes are at higher risk of gum disease, Danish study finds

2024-09-10
Gum disease is more common in individuals with microvascular complications of diabetes, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September) and published in The Journal of Dental Research has found. Periodontitis is a chronic inflammatory disease that affects the gums and the bones supporting the teeth. It is caused by the accumulation of bacterial plaque, and if left untreated, it can lead to the destruction of the tissues that hold the teeth in place, ultimately resulting in tooth loss. “This tooth loss can affect essential functions like chewing and speaking, while ...

Weight loss drug liraglutide is safe and effective in children under 12, study finds

2024-09-10
The obesity medication liraglutide is safe and effective in children aged 6 to <12 years, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September), and published simultaneously in the New England Journal of Medicine (NEJM), has found. Childen aged six to <12 years who took liraglutide for just over a year experienced a reduction in BMI of 7.4% compared to placebo and experienced improvements in blood pressure and blood sugar control. The results of ...

Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal

Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal
2024-09-10
Results from a clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) show a striking improvement for patients who received chemotherapy before surgery to remove advanced squamous cell-type cancer of the nose or sinus. The European Society of Medical Oncology is highlighting the trial at its ESMO Congress 2024 in Barcelona, Spain. Surgery is required for these patients but at a high physical cost. Patients enrolled in this trial had signs that surgery would result in loss of the eye, the base of the skull bone, or both. However, in the randomized prospective trial EA3163, patients receiving chemotherapy ...

The glug of it all

2024-09-10
As Rohit Velankar, now a senior at Fox Chapel Area High School, poured juice into a glass, he could feel that the rhythmic glug, glug, glug was flexing the walls of the carton. Rohit pondered the sound, and wondered if a container’s elasticity influenced the way its fluid drained. He initially sought the answer to his question for his science fair project, but it spiraled into something more when he teamed up with his father, Sachin Velankar, a professor of chemical and petroleum engineering at the University of Pittsburgh Swanson School of Engineering.  They set up an experiment ...

UTA to build netted drone facility in Fort Worth

UTA to build netted drone facility in Fort Worth
2024-09-10
The University of Texas at Arlington is expanding its research and innovation capabilities by building a $2.3 million, state-of-the-art outdoor netted drone facility. The Maverick Autonomous Vehicle Research Center (MAVRC) will be located at the UT Arlington Research Institute (UTARI) in Fort Worth, with a planned completion date of January 2025. “MAVRC will significantly and positively impact UTA’s presence in the region by supporting the university-industry-government-community ecosystem focused ...

Streamlining energy regulations on Native American reservations could help alleviate poverty

2024-09-10
MADISON–Land was once set aside as Native American reservations because it was undesirable and low in resources, but now interested Native Americans may have economic leverage in the growing industry of clean energy. A team of researchers led by UW–Madison professors Dominic Parker and Sarah Johnston quantified the economic potential of wind and solar energy projects on these lands and discussed the regulatory barriers for tribes wishing to tap into it. “This is the first comprehensive ...

LAST 30 PRESS RELEASES:

Arthropods dominate plant litter decomposition in drylands

World-renowned organic chemists attend inaugural science symposium hosted by Rice’s Global Paris Center

The trees of Miami’s future

MIT team takes a major step toward fully 3D-printed active electronics

Accelerated three-year medical school students perform as well as peers in traditional four-year programs

SwRI-developed instruments will study potential habitability of Jupiter’s moon Europa

Proposed scoring system may enhance equity in organ transplantation, increase transplant rates and improve patient survival

Survivors of childhood brain cancer are more likely to be held back in school

Updating offshore turbine designs to reflect storms’ complexity is key

Hospital strain during the COVID-19 pandemic and outcomes in older racial and ethnic minority adults

Scientists unveils key role of “selfish DNA” in early human development

Bonobos may be more vulnerable than previously thought, suggests genetics study

Scripps Research scientists discover chemical probes for previously “undruggable” cancer target

Giant Magellan telescope begins primary mirror support system testing

Experimental cancer drug eliminates bone metastases caused by breast cancer in lab models

Political candidates who fight climate change stand to benefit in election

Stand up to Cancer announces new grants supporting pioneering research in six cancer types

Researchers awarded $1.3M to help military Veterans battling Acute Myeloid Leukemia

New hub for high-energy astrophysics — CTAO Science Data Management Centre opens at DESY in Zeuthen

JMIR publications CEO and Executive Editor Gunther Eysenbach achieves #1 ranking as most cited researcher in Medical Informatics for fifth consecutive year

ERC grant for groundbreaking wearable health tech

NIH announces winners of prize competition to improve postpartum maternal health and health equity through innovative diagnostics

APS and SPR honor Dr. Cynthia F. Bearer with the 2025 Mary Ellen Avery Neonatal Research Award

Election delays and voter trust

US air pollution monitoring network has gaps in coverage, say researchers

Continuous monitoring of fatigue in factory workers

Farmer ants’ wearable bacteria

Political polarization and trust

Study uncovers how silkworm moth's odor detection may improve robotics

New study links obesity to elevated hypertension risk among young middle eastern women

[Press-News.org] "Cuddle hormone" oxytocin may provide pain relief and help curb harmful opioid use